Mcp-1, eNOS, tPA and PAI-1 gene polymorphism and correlation of genotypes and phenotypes in hepatopulmonary syndrome

Digestive Diseases and Sciences

Volumn 53, Issue 5, 2008, Pages 1345-1351

  Tumgor, Gokhan ^a   Berdeli, Afig ^a   Arikan, Cigdem ^a   Levent, Ertürk ^a   Aydogdu, Sema ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

eNOS; Hepatopulmonary syndrome; MCP 1; PAI 1; tPA

Indexed keywords

ASPARAGINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ALLELISM; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HEPATOPULMONARY SYNDROME; HETEROZYGOTE; HUMAN; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL;

ADOLESCENT; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HEPATOPULMONARY SYNDROME; HUMANS; INFANT; MALE; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TISSUE PLASMINOGEN ACTIVATOR;

EID: 41949133987     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-0002-3     Document Type: Article

References (45)

1. Krowka MJ (1997) Hepatopulmonary syndrome and portopulmonary hypertension: distinctions and dilemmas. Hepatology 25:1282-1284
2. Naeije R (2003) Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly 133:163-169
3. Tumgor G, Arikan A, Yuksekkaya HA, Levent E, Dorak C, Goksen D, Kilic M, Aydogdu S (2005) Childhood cirrhosis, hepatopulmonary syndrome and liver transplantation (abstract) 38th Annual meeting of the Europan Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), Porto
4. Whyte MK, Hughes JM, Peters AM, Ussov W, Patel S, Burroughs AK (1998) Analysis of intrapulmonary right to left shunt in the hepatopulmonary syndrome. J Hepatol 29:85-93
5. Krowka MJ, Dickson ER, Cortese DA (1993) Hepatopulmonary syndrome: clinical observations and lack of therapeutic response to somatostatin analogue. Chest 104:515-521
6. Nunes H, Lebrec D, Mazmanian M, Capron F, Heller J, Tazi KA, Zerbib E, Dulmet E, Moreau R, Dinh-Xuan AT, Simonneau G, Herve P (2001) Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med 164:879-885
7. Carter EP, Hartsfield CL, Miyazono M, Jakkula M, KG Morris, McMurtry IF (2002) Regulation of heme oxygenase-1 by nitric oxide during hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol 283:346-353
8. Strassburg CP (2003) Shock liver. Best Pract Res Clin Gastroenterol 17:369-381
9. Vallance P, Moncada S (1991) Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 337:776-778
10. Fallon MB, Abrams GA, Luo B, Hou Z, Dai J, Ku DD (1997) The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 113:606-614
11. Robalino RD, Moodie DS (1991) Association between primary pulmoner hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestation. J Am Coll Cardiol 17:492-498
12. Schenk P, Fuhrmann V, Madl C, Funk G, Lehr S, Kandel O, Muller C (2002) Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 51:853-859
13. Krowka MJ, Wiseman GA, Burnett OL, Spiver JR, Therneau T, Porayko MK, Wiesner RH (2000) Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanning. Chest 118:615-624
14. Martinez G, Barbera JA, Navasa M, Visa J, Rodriguez-Roisin R (1999) Hepatopulmonary syndrome associated with cardiorespiratory disease. J Hepatol 30:882-889
15. Rovin B, Lu L, Saxena R (1999) A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259:344-348
16. Traynor TR, Herring AC, Dorf ME, Kuziel WA, Toews GB, Huffnagle GB (2002) Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity. J Immunol 168:4659-4666
17. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ (2000) Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404:407-411
18. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, Lock G, Scholmerich J, Hellerbrand C (2003) A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver damage. Gastroenterology 125:1085-1093
19. Lee KN, Yoon SK, Lee JW, Kim KN, Park BH, Kwak JY, Jeong JS, Kim YH (2004) Hepatopulmonary syndrome induced by common bile duct ligation in a rabbit model: correlation between pulmonary vascular dilatation on thin-section CT and angiography and serum nitrite concentration or endothelial nitric oxide synthase (eNOS)1 expression. Korean J Radiol 5:149-156
20. Moncada S, Higgs A (1993) The l-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012
21. Schmidt HH, Walter U (1994) NO at work. Cell 78:919-925
22. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, Smits P (2002). The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 20:2023-2027
23. Iacoviello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C, Benedetta Donati M (1998). Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 338:79-85
24. Makalewski W, Mitchell GA, Labuda D (1994) Alu sequence in the coding regions of mRNA: a source of protein variability. Trends Genet 10:188-193
25. Juhan-Vague I, Alessi MC (1997) PAI-1, obesity, insulin resistance and the risk of cardiovascular events. Thromb Haemost 78:656-660
26. van den Eijnden-Schrauwen Y, Lakenberg N, Emeis JJ, de Knijff P (1995) Alu-repeat polymorphism in the tissue-type plasminogen activator (tPA) gene does not affect basal endothelial tPA synthesis. Thromb Haemost 74:1202
27. Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W (1999) The 4G/4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk of this disease. Thromb Haemost 82:1121-1126
28. Ioviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB (1998) The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 80:1029-1030
29. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851-1855
30. Grancha S, Estelles A, Tormo G, Falco C, Gilabert J, Espana F, Cano A, Sequi R, Aznar J (1999) Plasminogen activator inhibitor-1 promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 81:516-521
31. Mujynya-Ludunge K, Viswambharan H, Driscoll R, Ming XF, von Segesser LK, Kappenberger L, Yang Z, Vassalli G (2005) Endothelial nitric oxide synthase gene transfer restores endothelium-dependent relaxations and attenuates lesion formation in carotid arteries in apolipoprotein E-deficient mice. Basic Res Cardiol 100:102-111
32. Aguilar F, Gonzalez-Escribano MF, Sanchez-Roman J, Nunez-Roldan A (2001) MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens 58:335-338
33. Szalai C, Kozma GT, Nagy A, Bojszko A, Krikovszky D, Szabo T, Falus A (2001) Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol 108:375-381
34. Kruger B, Schroppel B, Ashkan R, Marder B, Zulke C, Murphy B, Kramer BK, Fischereder M (2002) Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 13:2585-2589
35. Herfarth H, Goke M, Hellerbrand C, Muhlbauer M, Vogl D, Scholmerich J, Rogler G (2003) Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. Int J Colorectal Dis 18:401-405
36. Rovin BH, Yoshiumura T, Tan L (1992) Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesengial cells. J Immunol 148:2148-2153
37. Mansfield MW, Stickland MH, Grant PJ (1995) Plasminogen activator inhibitor-1 promoter polymorphism and coronary artery disease in non-insulin dependent diabetes. Thromb Haemost 74:1032-1034
38. Margaglione M, Cappucci G, Colaizzo D, Guiliani N, Vecchione G, Grandone E, Pennelli O, Di Minno G (1998) The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 18:152-156
39. Seki T, Imai H, Uno S, Ariga T, Gelehrter TD (1996) Production of tissue-type plasminogen activator (t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in mildly cirrhotic rat liver. Thromb Haemost 75:801-807
40. Keishi K, Tazuma S, Nishioka T, Hyogo H, Chayama K (2005) Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Dig Dis Sci 50:942-948
41. Goh BJ, Tan BT, Hon WM, Lee KH, Khoo HE (2006) Nitric oxide synthase and heme oxygenase expressions in human liver cirrhosis. World J Gastroenterol 28:588-594
42. Ferreiro CR, Chagas AC, Carvalho MH, Dantas AP, Jatene MB, Bento De Souza LC, Lemos Da Luz P (2001) Influence of hypoxia on nitric oxide synthase activity and gene expression in children with congenital heart disease: a novel pathophysiological adaptive mechanism. Circulation 103:2272-2276
43. McQuillan L, Leung GK, Marsden PA, Kostyk SK, Kourembanas S (1994) Hypoxia inhibits expression of eNOS via transcriptional and posttranslational mechanisms. Am J Physiol 267:1921-1927
44. Phelan MW, Faller DV (1996) Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells. J Cell Physiol 167:469-476
45. Laufs U, La Fata VL, Liao JK (1997) Inhibition of 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272:31725-31729